Daraxonrasib, a new cancer drug, doubled survival time for metastatic pancreatic cancer patients to 13 months versus 7 months with chemotherapy in Phase 3 trials.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Dying of Cancer, Ben Sasse Says 'Miracle Drug' Shrank Tumors and Caused Bloody Face
13 Months months Median survival with daraxonrasib
7 Months months Median survival with chemotherapy
Randomized Phase 3 Trial type
Metastatic Pancreatic Cancer Cancer type
86% Increase survival time improvement